EdgeScore

GRI · Nasdaq

GRI Bio, Inc.: financial statements

Insufficient data · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2020: $100KNet income 2020: -$4.8M2020Revenue 2021: $0Net income 2021: -$9.3M2021
RevenueNet income

Operating and free cash flow

Operating cash flow 2020: -$3.7MFree cash flow 2020: -$3.7M2020Operating cash flow 2021: -$8.3MFree cash flow 2021: -$8.3M2021
Operating cash flowFree cash flow

Margins

Operating 2020: -4788.0%Net 2020: -4822.0%20202021
GrossOperatingNet

Returns

ROA 2020: -504.9%ROA 2021: -111.6%20202021
ROEROICROA

Income statement

USD20202021Last year
Revenue$100K$0-100%
Operating income-$4.8M-$9.3M-93%
EBITDA-$4.8M-$9.3M-93%
Interest expense$41.0K$29.0K-29%
Net income-$4.8M-$9.3M-93%

Cash flow

USD20202021Last year
Operating cash flow-$3.7M-$8.3M-124%
Capital expenditure$2.0K$0-100%
Free cash flow-$3.7M-$8.3M-124%

Balance sheet

USD20202021Last year
Cash$109K$3.7M+3296%
Current assets$674K$8.1M+1106%
Total assets$955K$8.3M+773%
Current liabilities$2.2M$2.4M+10%
Total liabilities$2.4M$2.5M+4%
Shareholders' equity-$1.5M-$4.8M-233%
Net debt-$109K-$3.7M-3296%

Ratios

20202021Last year
Operating margin-4788.0%—
Net margin-4822.0%—
Return on assets-504.9%-111.6%
Interest coverage-116.8x-319.3x
Current ratio0.303.32
Quick ratio0.303.32

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.